BiotechTube
Home/Pipeline/Bi-XDC with PROTACs

Bi-XDC with PROTACs

Oncology

IND-enablingActive

Key Facts

Indication
Oncology
Phase
IND-enabling
Status
Active
Company
Coherent Biopharma

About Coherent Biopharma

A clinical-stage biotech company developing bi-targeting XDC drugs to treat cancer and address undruggable targets.

View full company profile

Therapeutic Areas

Oncology

Other Oncology Drugs

DrugCompanyPhase
Bi-XDC with RPTCoherent BiopharmaEarly-stage
mRNA Anticancer VaccineSunshine BiopharmaPreclinical Research
Biosimilar BevacizumabOrganon (2)Phase 3
Biosimilar PembrolizumabOrganon (2)Phase 3
BCL-2 Inhibitor ProgramVincerx PharmaPreclinical
Not specified in provided content3SbioVarious
Preclinical ProjectsZion PharmaPreclinical
Attenukine Oncology CandidateTevaPhase 1
XEMA Tumor Marker ELISA KitXEMA GroupCommercial
KRAS inhibitorRisen Pharma TechPreclinical/Phase 1
KEAP1 Activator ProgramVividion TherapeuticsPhase 1
Bendamustine IntermediateAR Life ScienceCommercial